No Cover Image

Journal article 205 views 48 downloads

Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022

Nicola Caldwell Orcid Logo, Rana Afshar, Beatriz Baragaña Orcid Logo, Amaya L. Bustinduy, Conor R. Caffrey Orcid Logo, James J. Collins, Daniela Fusco, Amadou Garba, Mark Gardner, Mireille Gomes, Karl F. Hoffmann Orcid Logo, Michael Hsieh, Nathan C. Lo, Case W. McNamara Orcid Logo, Justin Komguep Nono, Gilda Padalino Orcid Logo, Kevin D. Read Orcid Logo, Meta Roestenberg, Thomas Spangenberg Orcid Logo, Sabine Specht, Ian H. Gilbert Orcid Logo

ACS Infectious Diseases, Volume: 9, Issue: 5, Pages: 1046 - 1055

Swansea University Author: Gilda Padalino Orcid Logo

  • 64494.VOR.pdf

    PDF | Version of Record

    Copyright © 2022 The Authors. Published by American Chemical Society. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).

    Download (4.68MB)

Check full text

DOI (Published version): 10.1021/acsinfecdis.3c00081

Abstract

In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an international meeting at the Wellcome Collection in London to explore the current clinical situation and challenges associated with treating schistosomiasis. The aim of this meeting was to discuss the need for n...

Full description

Published in: ACS Infectious Diseases
ISSN: 2373-8227 2373-8227
Published: American Chemical Society (ACS) 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa64494
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-10-04T16:17:16Z
last_indexed 2023-10-04T16:17:16Z
id cronfa64494
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>64494</id><entry>2023-09-08</entry><title>Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022</title><swanseaauthors><author><sid>7e5526209f02734f57ba19b0d17604ec</sid><ORCID>0000-0001-8580-1293</ORCID><firstname>Gilda</firstname><surname>Padalino</surname><name>Gilda Padalino</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-09-08</date><deptcode>PHAR</deptcode><abstract>In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an international meeting at the Wellcome Collection in London to explore the current clinical situation and challenges associated with treating schistosomiasis. The aim of this meeting was to discuss the need for new treatments in view of the clinical situation and to ascertain what the key requirements would be for any potential new anti-schistosomals. This information will be essential to inform ongoing drug discovery efforts for schistosomiasis. We also discussed the potential drug discovery pathway and associated criteria for progressing compounds to the clinic. To date, praziquantel (PZQ) is the only drug available to treat all species causing schistosomiasis, but it is often unable to completely clear parasites from an infected patient, partially due to its inactivity against juvenile worms. PZQ-mediated mass drug administration campaigns conducted in endemic areas (e.g., sub-Saharan Africa, where schistosomiasis is primarily prevalent) have contributed to reducing the burden of disease but will not eliminate the disease as a public health problem. The potential for Schistosoma to develop resistance towards PZQ, as the sole treatment available, could become a concern. Consequently, new anthelmintic medications are urgently needed, and this Perspective aims to capture some of the learnings from our discussions on the key criteria for new treatments.</abstract><type>Journal Article</type><journal>ACS Infectious Diseases</journal><volume>9</volume><journalNumber>5</journalNumber><paginationStart>1046</paginationStart><paginationEnd>1055</paginationEnd><publisher>American Chemical Society (ACS)</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2373-8227</issnPrint><issnElectronic>2373-8227</issnElectronic><keywords>Schistosomiasis, Schistosoma, neglected tropical disease, infectious disease, drug discovery, therapeutics, anthelmintics, target product profile</keywords><publishedDay>12</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-05-12</publishedDate><doi>10.1021/acsinfecdis.3c00081</doi><url>http://dx.doi.org/10.1021/acsinfecdis.3c00081</url><notes/><college>COLLEGE NANME</college><department>Pharmacy</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PHAR</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This meeting was funded by a Wellcome Trust award (222153/Z/20/Z) which also helped cover travel expenses for attendees from Low and Middle Income Countries.</funders><projectreference/><lastEdited>2023-11-14T15:22:50.8169336</lastEdited><Created>2023-09-08T15:56:17.0085794</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>Nicola</firstname><surname>Caldwell</surname><orcid>0000-0002-1049-4185</orcid><order>1</order></author><author><firstname>Rana</firstname><surname>Afshar</surname><order>2</order></author><author><firstname>Beatriz</firstname><surname>Baragaña</surname><orcid>0000-0002-0959-1113</orcid><order>3</order></author><author><firstname>Amaya L.</firstname><surname>Bustinduy</surname><order>4</order></author><author><firstname>Conor R.</firstname><surname>Caffrey</surname><orcid>0000-0003-3048-8572</orcid><order>5</order></author><author><firstname>James J.</firstname><surname>Collins</surname><order>6</order></author><author><firstname>Daniela</firstname><surname>Fusco</surname><order>7</order></author><author><firstname>Amadou</firstname><surname>Garba</surname><order>8</order></author><author><firstname>Mark</firstname><surname>Gardner</surname><order>9</order></author><author><firstname>Mireille</firstname><surname>Gomes</surname><order>10</order></author><author><firstname>Karl F.</firstname><surname>Hoffmann</surname><orcid>0000-0002-3932-5502</orcid><order>11</order></author><author><firstname>Michael</firstname><surname>Hsieh</surname><order>12</order></author><author><firstname>Nathan C.</firstname><surname>Lo</surname><order>13</order></author><author><firstname>Case W.</firstname><surname>McNamara</surname><orcid>0000-0002-5754-3407</orcid><order>14</order></author><author><firstname>Justin Komguep</firstname><surname>Nono</surname><order>15</order></author><author><firstname>Gilda</firstname><surname>Padalino</surname><orcid>0000-0001-8580-1293</orcid><order>16</order></author><author><firstname>Kevin D.</firstname><surname>Read</surname><orcid>0000-0002-8536-0130</orcid><order>17</order></author><author><firstname>Meta</firstname><surname>Roestenberg</surname><order>18</order></author><author><firstname>Thomas</firstname><surname>Spangenberg</surname><orcid>0000-0002-5654-8919</orcid><order>19</order></author><author><firstname>Sabine</firstname><surname>Specht</surname><order>20</order></author><author><firstname>Ian H.</firstname><surname>Gilbert</surname><orcid>0000-0002-5238-1314</orcid><order>21</order></author></authors><documents><document><filename>64494__28709__a533879f461c4ab087f91fabbe9cf04d.pdf</filename><originalFilename>64494.VOR.pdf</originalFilename><uploaded>2023-10-04T17:18:20.5243458</uploaded><type>Output</type><contentLength>4912415</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright © 2022 The Authors. Published by American Chemical Society. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 64494 2023-09-08 Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022 7e5526209f02734f57ba19b0d17604ec 0000-0001-8580-1293 Gilda Padalino Gilda Padalino true false 2023-09-08 PHAR In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an international meeting at the Wellcome Collection in London to explore the current clinical situation and challenges associated with treating schistosomiasis. The aim of this meeting was to discuss the need for new treatments in view of the clinical situation and to ascertain what the key requirements would be for any potential new anti-schistosomals. This information will be essential to inform ongoing drug discovery efforts for schistosomiasis. We also discussed the potential drug discovery pathway and associated criteria for progressing compounds to the clinic. To date, praziquantel (PZQ) is the only drug available to treat all species causing schistosomiasis, but it is often unable to completely clear parasites from an infected patient, partially due to its inactivity against juvenile worms. PZQ-mediated mass drug administration campaigns conducted in endemic areas (e.g., sub-Saharan Africa, where schistosomiasis is primarily prevalent) have contributed to reducing the burden of disease but will not eliminate the disease as a public health problem. The potential for Schistosoma to develop resistance towards PZQ, as the sole treatment available, could become a concern. Consequently, new anthelmintic medications are urgently needed, and this Perspective aims to capture some of the learnings from our discussions on the key criteria for new treatments. Journal Article ACS Infectious Diseases 9 5 1046 1055 American Chemical Society (ACS) 2373-8227 2373-8227 Schistosomiasis, Schistosoma, neglected tropical disease, infectious disease, drug discovery, therapeutics, anthelmintics, target product profile 12 5 2023 2023-05-12 10.1021/acsinfecdis.3c00081 http://dx.doi.org/10.1021/acsinfecdis.3c00081 COLLEGE NANME Pharmacy COLLEGE CODE PHAR Swansea University This meeting was funded by a Wellcome Trust award (222153/Z/20/Z) which also helped cover travel expenses for attendees from Low and Middle Income Countries. 2023-11-14T15:22:50.8169336 2023-09-08T15:56:17.0085794 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy Nicola Caldwell 0000-0002-1049-4185 1 Rana Afshar 2 Beatriz Baragaña 0000-0002-0959-1113 3 Amaya L. Bustinduy 4 Conor R. Caffrey 0000-0003-3048-8572 5 James J. Collins 6 Daniela Fusco 7 Amadou Garba 8 Mark Gardner 9 Mireille Gomes 10 Karl F. Hoffmann 0000-0002-3932-5502 11 Michael Hsieh 12 Nathan C. Lo 13 Case W. McNamara 0000-0002-5754-3407 14 Justin Komguep Nono 15 Gilda Padalino 0000-0001-8580-1293 16 Kevin D. Read 0000-0002-8536-0130 17 Meta Roestenberg 18 Thomas Spangenberg 0000-0002-5654-8919 19 Sabine Specht 20 Ian H. Gilbert 0000-0002-5238-1314 21 64494__28709__a533879f461c4ab087f91fabbe9cf04d.pdf 64494.VOR.pdf 2023-10-04T17:18:20.5243458 Output 4912415 application/pdf Version of Record true Copyright © 2022 The Authors. Published by American Chemical Society. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0). true eng https://creativecommons.org/licenses/by/4.0/
title Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
spellingShingle Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
Gilda Padalino
title_short Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
title_full Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
title_fullStr Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
title_full_unstemmed Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
title_sort Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
author_id_str_mv 7e5526209f02734f57ba19b0d17604ec
author_id_fullname_str_mv 7e5526209f02734f57ba19b0d17604ec_***_Gilda Padalino
author Gilda Padalino
author2 Nicola Caldwell
Rana Afshar
Beatriz Baragaña
Amaya L. Bustinduy
Conor R. Caffrey
James J. Collins
Daniela Fusco
Amadou Garba
Mark Gardner
Mireille Gomes
Karl F. Hoffmann
Michael Hsieh
Nathan C. Lo
Case W. McNamara
Justin Komguep Nono
Gilda Padalino
Kevin D. Read
Meta Roestenberg
Thomas Spangenberg
Sabine Specht
Ian H. Gilbert
format Journal article
container_title ACS Infectious Diseases
container_volume 9
container_issue 5
container_start_page 1046
publishDate 2023
institution Swansea University
issn 2373-8227
2373-8227
doi_str_mv 10.1021/acsinfecdis.3c00081
publisher American Chemical Society (ACS)
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy
url http://dx.doi.org/10.1021/acsinfecdis.3c00081
document_store_str 1
active_str 0
description In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an international meeting at the Wellcome Collection in London to explore the current clinical situation and challenges associated with treating schistosomiasis. The aim of this meeting was to discuss the need for new treatments in view of the clinical situation and to ascertain what the key requirements would be for any potential new anti-schistosomals. This information will be essential to inform ongoing drug discovery efforts for schistosomiasis. We also discussed the potential drug discovery pathway and associated criteria for progressing compounds to the clinic. To date, praziquantel (PZQ) is the only drug available to treat all species causing schistosomiasis, but it is often unable to completely clear parasites from an infected patient, partially due to its inactivity against juvenile worms. PZQ-mediated mass drug administration campaigns conducted in endemic areas (e.g., sub-Saharan Africa, where schistosomiasis is primarily prevalent) have contributed to reducing the burden of disease but will not eliminate the disease as a public health problem. The potential for Schistosoma to develop resistance towards PZQ, as the sole treatment available, could become a concern. Consequently, new anthelmintic medications are urgently needed, and this Perspective aims to capture some of the learnings from our discussions on the key criteria for new treatments.
published_date 2023-05-12T15:22:54Z
_version_ 1782553378522398720
score 11.016235

Similar Items